Compare NSSC & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSSC | ANAB |
|---|---|---|
| Founded | 1969 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 1994 | 2015 |
| Metric | NSSC | ANAB |
|---|---|---|
| Price | $37.16 | $59.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 12 |
| Target Price | $48.17 | ★ $71.67 |
| AVG Volume (30 Days) | 379.4K | ★ 475.3K |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ 0.70 | N/A |
| Revenue | $181,621,000.00 | ★ $234,603,000.00 |
| Revenue This Year | $13.63 | N/A |
| Revenue Next Year | $10.05 | $52.14 |
| P/E Ratio | $53.56 | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $26.44 | $17.11 |
| 52 Week High | $47.61 | $73.30 |
| Indicator | NSSC | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 48.52 | 56.20 |
| Support Level | $34.77 | $43.75 |
| Resistance Level | $38.07 | $67.69 |
| Average True Range (ATR) | 1.15 | 2.65 |
| MACD | 0.45 | 1.01 |
| Stochastic Oscillator | 69.91 | 93.10 |
NAPCO Security Technologies Inc manufactures security products, encompassing access control systems, door-locking products, intrusion and fire alarm systems and video surveillance products. Its products are used for various applications which includes alarm systems like automatic communicators, combination control panels/digital communicators and digital keypad systems, fire alarm control panel and area detectors mainly used for commercial, residential, institutional, industrial and governmental uses. Geographically, the company derives a majority of its revenue from the United States.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).